Thomas Flaig, MD, on the Role of Antibody-Drug Conjugates in Advanced Urothelial Cancer

Posted: Wednesday, May 10, 2023

Thomas Flaig, MD, of Anschutz Medical Campus, Aurora, Colorado, discusses the clinical settings in which two antibody-drug conjugates—enfortumab vedotin-ejfv and sacituzumab govitecan-hziy—are being used in the treatment of advanced urothelial cancer. Data on the use of these agents alone in combination with immunotherapy are emerging, he added.

---